Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19
2024 · New England Journal of Medicine · 120 citations
https://doi.org/10.1056/nejmoa2309003
M
Mary Lynn Baniecki
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
39
Papers
1.6K
Citations
13
h-index
18
i10-index
Mary Lynn Baniecki is an academic researcher from Pfizer (United States). The author has contributed to research in topics: SARS-CoV-2 and COVID-19 Research & COVID-19 Clinical Research Studies & Malaria Research and Control. The author has an h-index of 13, co-authored 34 publications.
ORCID: 0000-0003-3862-7231Papers by this author
worksOral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19
2024 · New England Journal of Medicine · 27 citations
https://doi.org/10.1056/nejmoa2309002
Characterization of Plasmodium falciparum structure in Nigeria with malaria SNPs barcode
2018 · Malaria Journal · 18 citations
https://doi.org/10.1186/s12936-018-2623-8
Virologic Response and Safety of Ibuzatrelvir, A Novel SARS-CoV-2 Antiviral, in Adults With COVID-19
2024 · Clinical Infectious Diseases · 10 citations
https://doi.org/10.1093/cid/ciae529
Additional file 1 of Use of a Plasmodium vivax genetic barcode for genomic surveillance and parasite tracking in Sri Lanka
2020 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.12986808
Additional file 2 of Use of a Plasmodium vivax genetic barcode for genomic surveillance and parasite tracking in Sri Lanka
2020 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.12986811
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat